TG Therapeutics (TGTX) Set to Report Quarterly Earnings

TG Therapeutics (NASDAQ:TGTX) is scheduled to release its earnings report before the market opens on Monday, November 4th. Analysts are predicting that the company will announce earnings of $0.04 per share for the quarter.

Recent Earnings Performance

The last earnings report from TG Therapeutics was released on August 6th. In that quarter, the biopharmaceutical firm posted earnings of $0.04 per share, surpassing the analysts' consensus estimate of a loss of $0.04 by $0.08. The company achieved a return on equity of 57.73% and noted a net margin of 27.60%. TG Therapeutics also generated revenue of $73.47 million for that quarter, which was higher than the expected $65.92 million. This revenue represented an impressive increase of 357.0% compared to the same quarter last year, which reported a loss of $0.34 per share.

Current Market Performance

As of Friday, shares of TG Therapeutics were trading at $26.90. The company has a market capitalization of approximately $4.16 billion, with a price-to-earnings ratio of 44.10. The stock has demonstrated volatility, reflected in its beta of 2.21. Furthermore, TG Therapeutics has a debt-to-equity ratio of 0.58 and its financial ratios show a strong current ratio of 3.58 and a quick ratio of 2.83. Over the past year, the stock has fluctuated between a low of $9.81 and a high of $26.99, with 50-day and 200-day moving averages of $23.51 and $20.01, respectively.

Analyst Opinions and Ratings

Various analysts have commented on TG Therapeutics stock. The Goldman Sachs Group recently raised their price target from $18.00 to $20.00 while maintaining a "neutral" rating. Additionally, TD Cowen has initiated coverage with a "buy" rating and a price target of $50.00. HC Wainwright also reaffirmed a "buy" rating, setting a price target of $49.00. B. Riley increased their price objective from $29.00 to $34.00, recommending the stock as a buy. According to MarketBeat data, two analysts have given the stock a hold rating, while five have assigned it a buy rating, resulting in a moderate buy average rating and an average price target of $36.33.

About TG Therapeutics

TG Therapeutics, Inc. is a biopharmaceutical company that is commercially focused on acquiring, developing, and marketing innovative therapies for B-cell mediated diseases both in the United States and internationally. One of its key products is BRIUMVI, an anti-CD20 monoclonal antibody aimed at treating adult patients with various forms of multiple sclerosis.

TG, Therapeutics, Earnings